A high-growth biotech giant with massive cash reserves driving innovation in neuroscience and cancer therapies while generating consistent double-digit billions in annual revenue.
Investors should consider this stock for its exceptional cash generation capability with operating cash flow of $4.98B and a net profit margin exceeding 30%, which provides ample capital to fund an extensive R&D pipeline without dilution.
The valuation may be stretched given the company's heavy reliance on a single blockbuster drug class, and the massive common share repurchases of $3.44B suggest management believes current shares are overvalued relative to intrinsic value.
Regeneron Pharmaceuticals, Inc. is a global biotechnology leader specializing in neurology, oncology, immunology, and ophthalmology, delivering breakthrough treatments through its proprietary Regeneron Institute of Living Medicine.
Management executed a strong financial performance in 2025, posting net income of $4.50B on top of record revenue growth from $12.17B in 2022 to $14.34B last year, demonstrating the scalability of their core ophthalmology franchise.
The pharmaceutical sector is currently undergoing a transition period where biotechnology firms must navigate patent expirations while investing heavily in research and development to maintain market leadership positions against generic competition.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $12.17B | $13.12B | $14.20B | $14.34B |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $12.17B | $13.12B | $14.20B | $14.34B |
| Operating Expenses | $7.43B | $9.07B | $10.21B | $10.77B |
| Operating Income | $4.74B | $4.05B | $3.99B | $3.58B |
| R&D | $3.59B | $4.44B | $5.13B | $5.85B |
| G&A | $2.12B | $2.63B | $2.95B | $2.70B |
| Stock-Based Comp | $725.0M | $885.0M | $982.8M | $993.7M |
| D&A | $341.4M | $421.0M | $482.9M | $543.7M |
| Amortization | — | $92.2M | $128.9M | $178.8M |
| Other OpEx | $1.73B | $2.00B | $2.12B | $2.21B |
| Non-Operating Income | $119.9M | $152.2M | $789.2M | $1.65B |
| Interest Expense | $59.4M | $73.0M | — | — |
| Pre-Tax Income | $4.86B | $4.20B | $4.78B | $5.23B |
| Income Tax | $520.4M | $245.7M | $367.3M | $725.8M |
| Continuing Ops | $4.34B | $3.95B | $4.41B | $4.50B |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $4.34B | $3.95B | $4.41B | $4.50B |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $4.34B | $3.95B | $4.41B | $4.50B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $15.88B | $19.48B | $18.66B | $18.02B |
| Cash & Equivalents | $3.11B | $2.73B | $2.49B | $3.12B |
| Marketable Securities | $4.64B | $8.11B | $6.52B | $5.49B |
| Accounts Receivable | $5.33B | $5.67B | $6.21B | $5.74B |
| Inventory | $2.40B | $2.58B | $3.09B | $3.20B |
| Prepaid Expenses | $411.2M | $386.6M | $349.2M | $474.8M |
| Other Current Assets | $0 | $0 | $0 | $0 |
| Long-Term Assets | $13.33B | $13.60B | $19.10B | $22.54B |
| Intangibles | $915.5M | $1.04B | $1.15B | $1.26B |
| Operating Leases | — | $78.0M | $217.4M | $245.8M |
| LT Securities | $6.59B | $5.40B | $8.90B | $10.26B |
| Other LT Assets | $5.82B | $7.09B | $8.83B | $10.77B |
| Total Assets | $29.21B | $33.08B | $37.76B | $40.56B |
| Current Liabilities | $3.14B | $3.42B | $3.94B | $4.37B |
| Accounts Payable | $589.2M | $606.6M | $789.5M | $939.0M |
| Current Leases | — | $19.0M | $30.3M | $37.8M |
| Deferred Revenue | $477.9M | $458.9M | $627.7M | $553.0M |
| Other Current Liab | $2.07B | $2.34B | $2.50B | $2.84B |
| Long-Term Liabilities | $3.41B | $3.68B | $4.46B | $4.93B |
| Long-Term Debt | $1.98B | $1.98B | $1.98B | $1.99B |
| LT Operating Leases | — | $68.7M | $204.1M | $229.0M |
| Other LT Liab | $1.36B | $1.51B | $2.09B | $2.51B |
| Total Liabilities | $6.55B | $7.11B | $8.41B | $9.30B |
| Shareholders' Equity | $22.66B | $25.97B | $29.35B | $31.26B |
| Paid-In Capital | $9.95B | $11.35B | $12.86B | $13.99B |
| Retained Earnings | $23.31B | $27.26B | $31.67B | $35.80B |
| AOCI | $-238.8M | $-80.9M | $-7.9M | $77.5M |
| Total L&E | $29.21B | $33.08B | $37.76B | $40.56B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $4.34B | $3.95B | $4.41B | $4.50B |
| Non-Cash Adjustments | $-101.2M | $-1.56B | $-3.29B | $-1.15B |
| Working Capital Changes | $777.7M | $2.20B | $3.30B | $1.62B |
| Cash from Operations | $5.01B | $4.59B | $4.42B | $4.98B |
| Cash from Investing | $-3.78B | $-3.19B | $-2.47B | $-629.1M |
| Debt Issuances | $0 | — | — | — |
| Share Buybacks | $2.08B | $2.23B | $2.60B | $3.44B |
| Dividends Paid | — | — | — | $370.3M |
| Cash from Financing | $-1.01B | $-1.79B | $-2.20B | $-3.72B |
| FX Effect | $0 | $-400.0K | $-700.0K | $300.0K |
| Net Change in Cash | $221.3M | $-381.6M | $-248.8M | $634.7M |
| Beginning Cash | $2.90B | $3.12B | $2.74B | $2.49B |
| Ending Cash | $3.12B | $2.74B | $2.49B | $3.12B |
The company operates primarily through four key therapeutic areas: Neurology, Oncology, Immunology, and Ophthalmology, which collectively generated $14.34B in gross profit, supported by significant R&D investments of $5.85B to advance pipeline assets.
Intense patent cliffs on blockbuster drugs like Eylea could significantly impact future revenue streams; rising R&D costs of $5.85B may delay commercialization of next-generation therapies; potential regulatory hurdles for new oncology and immunology indications in the US and Europe; and exposure to clinical trial failures typical of high-risk biotech development.
Regeneron possesses a formidable moat driven by its Regeneron Institute of Living Medicine, which integrates discovery and development; a dominant market position in the Eylea ophthalmology franchise providing recurring revenue stability; and a robust balance sheet with $3.12B in cash enabling aggressive share buybacks of $3.44B.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.